Compositions and uses thereof
US-9663517-B2 · May 30, 2017 · US
Compounds and methods for kinase modulation, and indications therefor
US11337976B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11337976-B2 |
| Application number | US-201715435569-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 17, 2017 |
| Priority date | Feb 7, 2011 |
| Publication date | May 24, 2022 |
| Grant date | May 24, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compounds active on protein kinases are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating a subject with a B-Raf mediated disease or condition, said method comprising administering to said subject an effective amount of a compound of formula: or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: each R 11 is independently halogen; Q is H or F; and m is 0, 1 or 2, wherein the B-Raf mediated disease or condition is melanoma, colon cancer, thyroid cancer, ovarian cancer, non-small-cell lung cancer, hepatocellular carcinoma, gastrointestinal stromal cell tumors, multiple myeloma, chronic myeloid leukemia, acute myeloid leukemia, or glioma. 2. The method of claim 1 , wherein R 11 is fluoro. 3. The method of claim 1 , wherein Q is H. 4. The method of claim 1 , wherein Q is fluoro. 5. The method of claim 1 , wherein m is 0. 6. The method of claim 1 , wherein m is 1. 7. The method of claim 1 , wherein the compound is: or a pharmaceutically acceptable salt thereof. 8. The method of claim 1 , wherein said disease or condition is melanoma. 9. The method of claim 1 , wherein said disease or condition is non-small cell lung cancer. 10. The method of claim 1 , wherein said disease or condition is colon cancer.
Assignees
Inventors
Classifications
Drugs for disorders of the respiratory system · CPC title
Antiasthmatics · CPC title
- C07D471/04Primary
Ortho-condensed systems · CPC title
for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11337976B2 cover?
- Compounds active on protein kinases are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.
- Who is the assignee on this patent?
- Plexxikon Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D471/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).